DR. BENJAMIN SAMUEL KLEIN, PH.D.
Social Work at 92 St, New York, NY

2010011, May 6, 2010

Dec 31, 2008

12/317784

Benjamin Y. Klein - New York NY, US

C12N 15/00

435455

A method to divert glucose away from glycolysis is described. The method is based on a planned “glucose sink” by introduction, into tumor cells, of nucleotide sequences from known genes whose products are comprised in lactose synthase enzymatic complex. The method is a process designed to correct, replenish or de novo induce lactose synthesis in cancer cells planned to be achieved by insertion of the cDNA of missing protein products capable of lactose synthesis by an expression vector under a strong promoter/enhancer. Intended introduction of the said enzyme expression system by a vector into the cancer cells is by transfection in culture for research. For therapeutic use introduction in vivo is intended by transvection/infection via nanotechnological delivery or viral delivery when delivery systems will be authorized. The best embodiment of this method is in medicine/veterinary where it may require a diagnostic step that defines in individual tumors, especially in mammary tumors, the quantitative and qualitative expression of endogenous genes that enable lactose synthesis, including mainly β4GalT1, α-lactalbumin, and galactose-generating glucose-epimerase, originating preferably from the same species in the case of human subjects. Expression deficiency, deletions, mutations or absence of one of these genes is a guide for induction, correction (if mutated) or replenishment.